Statistical Modelling of Waning Immunity After Shanchol™ Vaccination: A Prospective Cohort Study
<b>Introduction</b>: Cholera remains a major public health threat in endemic settings, and oral cholera vaccine (Shanchol™) campaigns are increasingly used amid constrained global supply. However, practical decisions on revaccination require clearer, setting-specific estimates of how rapidly vaccine-induced vibriocidal antibodies peak and wane. <b>Methods</b>: We conducted a prospective cohort kinetics analysis in Lukanga Swamps (Central Province, Zambia), enrolling adults (18-65 years) stratified by prior Shanchol™ exposure (0, 1, or 2 previous doses). All participants received two Shanchol™ doses 14 days apart, with serum collected at baseline and days 14, 28, 60, and 90 (end of follow-up). Ogawa and Inaba vibriocidal titres were measured using a complement-based assay and analysed on the log10 scale. Serotype-specific mixed-effects models with natural cubic splines for time (knots: 14, 28, 60 days) assessed trajectories by prior-dose strata, adjusting for age, sex, and HIV status. Peak timing and post-peak half-life were derived from model-based predictions with participant-level bootstrap CIs (1000 replications). <b>Results</b>: The analysis included 225 participants: 68 (30.2%) with zero prior doses, 89 (39.6%) with one, and 68 (30.2%) with two; median age was 33 years (IQR 25-49), 56.4% were female, and 19.2% were HIV-positive. Modelled titres for both serotypes rose steeply after vaccination, peaking around day 36-37 across prior-dose strata. Ogawa titres reached half of peak by about day 73-78, corresponding to post-peak half-lives of 37-41 days; Inaba declined more slowly with half-lives of 42-46 days. Confidence intervals overlapped across prior-dose strata, indicating minimal differences by vaccination history. <b>Conclusions</b>: In this cholera-endemic adult population, Shanchol™ induced vibriocidal responses that peaked at ~5 weeks and waned over the following 5-7 weeks, with broadly similar kinetics regardless of prior vaccination and slightly slower decay for Inaba than Ogawa. These parameters can inform booster timing in hotspot settings.
Authors
- Mwelwa Chibuye (ORCID: https://orcid.org/0000-0002-7609-9698)
- Kennedy Chibesa (ORCID: https://orcid.org/0000-0002-9539-4756)
- Sack Da
- Mutinta Muchimba (ORCID: https://orcid.org/0000-0003-3163-712X)
- Charlie Chaluma Luchen (ORCID: https://orcid.org/0000-0002-3093-4635)
- Fraser Liswaniso (ORCID: https://orcid.org/0000-0002-7257-9491)
- Roma Chilengi
- Bernard Phiri (ORCID: https://orcid.org/0009-0005-2657-8913)
- Harriet Ng’ombe
- Dennis Ngosa
- Amanda K. Debes
Institutions
- Centre for Infectious Disease Research in Zambia (ZM)
- University of Ghana (GH)
- Johns Hopkins University (US)
- Stellenbosch University (ZA)
- University of the Free State (ZA)
- Wellcome Sanger Institute (GB)
- University of Zambia (ZM)
- Amsterdam Institute for Global Health and Development (NL)
- National Institute of Public Administration (ZM)
Publication Details
- Journal
- Vaccines
- Published
- 2026-01-30
- DOI
- https://doi.org/10.3390/vaccines14020147
- Primary Topic
- Vibrio bacteria research studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00